Stocksigma LogoStocksigma Logo

Akums Drugs Reports Strong Q2 FY27 With PAT Surging 168% YoY

Akums Drugs & Pharmaceuticals delivered strong Q2 FY27 results, with revenue rising 31.9% YoY to Rs 1,342 cr and EBITDA surging 106.1% YoY to Rs 195 cr

Akums Drugs Reports Strong Q2 FY27 With PAT Surging 168% YoY

Akums Drugs and Pharmaceuticals Ltd 路 Investor Presentation 路 02 Nov 2026, 11:47 pm

Akums Drugs Reports Strong Q2 FY27 With PAT Surging 168% YoY Akums Drugs & Pharmaceuticals delivered strong Q2 FY27 results, with revenue rising 31.9% YoY to Rs 1,342 cr and EBITDA surging 106.1% YoY to Rs 195 cr (margins expanding 520 bps to 14.5%). PAT jumped 168.3% YoY to Rs 115 cr. Growth was spearheaded by the core CDMO segment (83.1% revenue share), which expanded 38.6% YoY to Rs 1,115 cr with EBITDA of Rs 168 cr. For H1 FY27, revenue reached Rs 2,509 cr (+22.9% YoY) and PAT doubled to Rs 216 cr, driving annualized ROE to 12.2% and ROCE to 19.4%.

Original exchange filing (PDF)

More announcements from Akums Drugs and Pharmaceuticals Ltd

All Akums Drugs and Pharmaceuticals Ltd announcements